Evidence map›Paper›PMID 35125217›Full record

ReviewClinical therapeutics2022

Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.

Sasha Deutsch-Link, Andrew M Moon, Yue Jiang, A Sidney Barritt, Elliot B Tapper

Open access · greenAbstract readReview
In one paragraph

Review in Clinical therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Ammonia-to-Urea Ratio: A Noninvasive First-Line Tool for Detecting Clinically Significant Portal Hypertension.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sasha Deutsch-LinkDivision of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: Sasha.Deutsch-Link@unchealth.unc.edu.
Andrew M MoonDivision of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Yue JiangDepartment of Statistical Science, Duke University, Durham, North Carolina.
A Sidney BarrittDivision of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Elliot B TapperDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan; Gastroenterology Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
University of North Carolina at Chapel Hill · USDuke University · USUniversity of Michigan · US

Funding

DIGESTIVE DISEASES EPIDEMIOLOGY TRAINING PROGRAMT32DK007634 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1990 to 2026
$7.4M
NIDDK NIH HHS T32 DK007634
6 · The paper itself

Abstract

purposeAmmonia is central to the pathophysiology of hepatic encephalopathy (HE) in cirrhosis. Serum ammonia levels have prognostic value and have been implicated in sarcopenia, hepatotoxicity, and immune dysfunction. Studies indicate that clinicians frequently order serum ammonia levels in decompensated cirrhosis; however, the clinical utility of serum ammonia levels has been questioned, citing challenges in accurate measurement and interpretation. This article involves a primary review of the literature to evaluate the importance of serum ammonia in cirrhosis and examines the clinical utility of serum ammonia levels in the management of HE. In addition to the review, we conducted primary research using national claims data to investigate national trends in practitioner use of serum ammonia.

methodsWe identified all hospitalizations in a national commercial claims database with and without ammonia testing among adults with noncirrhotic chronic liver disease and cirrhosis from January 1, 2007, to September 31, 2015. We calculated the proportion of hospitalizations with ammonia testing and the number of ammonia tests per 1000 hospital-days.

findingsProportion of hospitalizations with ammonia testing and ammonia tests per 1000 inpatient-days increased significantly from 2007 to 2015, and particularly in 2014 and 2015, for all groups. IMPLICATIONS: A review of the literature indicated that elevated serum ammonia contributes to neurotoxicity, sarcopenia, and immune dysfunction in cirrhosis. However, serum ammonia testing has not had consistent benefit in clinical diagnosis or management of HE in cirrhosis. Claims data indicated that ammonia testing increased substantially during the study period, particularly after the advent of electronic medical record systems. The rapid increase in testing may suggest that electronic health records play a crucial role in test volume by facilitating easy ordering and could be leveraged to improved value-based serum ammonia ordering. Serum ammonia levels may also benefit from standardized guidelines on collection, laboratory analysis, and interpretation.

Indexed as

Hepatic EncephalopathyHyperammonemiaSarcopeniaAdultAmmoniaHumansLiver CirrhosisAmmoniaAmmoniaCirrhosisHepatic encephalopathyLiver disease

Identifiers

PMID35125217
PMCPMC9050925
OpenAlexW4210638491

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.